← boardnext 2026-08-01
ATAI
atai Therapeutics, Inc.distress 5/10 · elevated risk$7.170%today-1% from 52w high
Psychiatry / CNS 1
Lead: treatment-resistant depression · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$43M
Runway
0.4 yrs
Shares 1y
+1%
Price & events
+80.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
+0.2%
1W
+74.8%
1M
+50.2%
3M
+72.7%
6M
+84.7%
1Y
+356.4%
2Y
-58.8%
5Y
-63.2%
All
Overview
- Market Cap
- $2.64B
- Enterprise Value
- $2.59B
- Volume
- 502.58K
- 52 Week Range
- $2.62 – $7.22
- Total Shares
- 368.17M
- Float Shares
- 305.91M
- Short %
- 9.71%
- % Held by Insiders
- 2.35%
- % Held by Institutions
- 43.89%
- RVOL
- 0.03x
- Beta
- 1.57
Pipeline stages · 1 programs
VLS-01-203 BU
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-01 Estimated 50% readout ~2026-09-15 | Phase 2 | VLS-01-203 BU | Treatment Resistant Depression | — | recruiting |
Catalyst news & presentations · 8
- H2'26Guided 55%readoutPhase 2VLS-01 · Topline data from Elumina Phase 2 trialSEC 8-K
- Q4'26Guided 70%readoutPhase 2BPL-003 · Initial data from additional cohort in Phase 2a studySEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-15partnershipMerger agreement with Eli Lilly; AtaiBeckley to be acquired for $6.75/share plus CVRsSEC 8-K
- Q2'26trial initiationsecondaryPhase 3BPL-003 · Phase 3 trial initiation pending EOP2 meeting outcomeSEC 8-K
- Q1'26readoutPhase 2EMP-01 · Topline data from exploratory Phase 2a studySEC 8-K
- March 6, 2026conferencedata presentationsecondaryBPL-003 · Virtual Investor Day focused on BPL-003 Phase 3 development strategySEC 8-K
- 2025-11-05partnershipAcquisition of Beckley Psytech consummated.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $12 (+64% upside) · 8 analysts
- 2026-07-20HC Wainwright & Co.Buy → Neutral
- 2026-07-17Jones TradingBuy → Hold
- 2026-07-17GuggenheimBuy → Neutral
- 2026-07-17JefferiesBuy → Hold
- 2026-07-16Canaccord GenuityBuy → Hold
- 2026-07-16NeedhamBuy → Hold
Competitors — treatment-resistant depression
Recent news
- 2026-07-22ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly - Stocktwits
- 2026-07-22How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33% - Yahoo! Finance Canada
- 2026-07-21Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? - PR Newswire
- 2026-07-21H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal - Investing.com
- 2026-07-20ATAIBECKLEY INC : BERENBERG CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $7.45 FROM $14 - Bitget
- 2026-07-20AtaiBeckley (ATAI) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
- 2026-07-20ATAIBECKLEY INC : TD COWEN CUTS TO HOLD FROM BUY - Bitget
- 2026-07-20Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.